ClinicalTrials.gg
CompletedNCT02774902Updated May 17, 2016

TAK-438_110 Drug Interaction With Cytochrome P450 3A4 (CYP3A4) Inhibitor Clarithromycin

A Phase 1 interventional study of TAK-438 and Clarithromycin in Healthy Volunteers, sponsored by Takeda. Completed. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-05-17.

Sponsored by Takeda · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluate the effect of multiple oral doses of clarithromycin on the pharmacokinetics of TAK-438 and its metabolites in healthy male adult participants following a single oral dose of TAK-438.

Read the detailed description

The drug being tested in this study is called TAK-438. TAK 438 is being tested to assess the effect of multiple oral doses of clarithromycin on the pharmacokinetics of TAK-438.

The study will enroll approximately 16 healthy adult male participants of non-Japanese origin. Participants will be assigned:

  • TAK-438 40 mg
  • Clarithromycin 500 mg

All participants will be asked to take 2 tablet of TAK-438 20 mg orally, once on Days 1 and 8 along with Clarithromycin 500 mg, tablets, orally twice daily from Days 3 to 9.

This single center trial will be conducted in Europe. The overall time to participate in this study is maximum of 44 days. Participants will be confined to site for 10 days, and a final visit after 4 days after discharge from the unit for a follow-up assessment.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Is a healthy adult male participant, of non-Japanese origin.
  4. Is aged 18 to 45 years, inclusive, at the time of informed consent and first study medication dose.
  5. Weighs at least 45 kg and has a (BMI) between 18 and 30 kg/m\^2, inclusive at Screening.
  6. A male participant who is sexually active with a female partner of agrees to use adequate from signing of informed consent throughout the duration of the study and for 12 weeks after last dose.
  7. Has clinical laboratory evaluations (including clinical chemistry, hematology, and urinalysis), within the reference range for the testing laboratory. Participants with evaluations outside the reference range that are deemed not by the investigator may be included at investigator discretion unless these are specifically identified in the exclusion criteria.
  8. Is willing to abstain from caffeine and alcohol from 72 hours before first dose (Day 1) until the Follow-up call.
  9. Is willing to abstain from strenuous exercise from 72 hours before first dose (Day 1) until the Follow-up call.
  10. Is willing to provide a sample for pharmacogenomic analysis.

Exclusion criteria

Exclusion Criteria:

  1. Has received any compound within 90 days prior to the first dose on Day 1.
  2. Has received TAK-438 in a previous clinical study or as a therapeutic agent.
  3. Is an immediate family member, study site employee, or in a dependant relationship with a study site employee who is involved in the conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  4. Has a known or allergies to clarithromycin or any associated .
  5. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 5 years prior to the Screening Visit or is unwilling to agree to abstain from alcohol and drugs throughout the study.
  6. Has taken or is required to take any excluded medication.
  7. Intends to donate sperm during the course of this study or for 12 weeks thereafter.
  8. Has evidence of current cardiovascular, central nervous system, hepatic, hematopoietic disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy, asthma hypoxemia, hypertension, seizures, or allergic skin rash. There is any finding in the participant's medical history, physical examination, or safety laboratory tests giving reasonable suspicion of a disease that would contraindicate taking TAK-438, or a similar drug in the same class, or clarithromycin, or that might interfere with the conduct of the study. This includes, but is not limited to, peptic ulcer disease, seizure disorders, and cardiac arrhythmias.
  9. Has a history or clinical manifestations of significant symptomatic, gastroesophageal reflux disease (GERD), erosive esophagitis (EE), duodenal ulcer, gastric ulcer, dyspepsia, Barrett esophagus (BE), or Zollinger-Ellison syndrome.
  10. Has current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (ie, a history of malabsorption, esophageal reflux, peptic ulcer disease, EE frequent [more than once per week], occurrence of heartburn, or any surgical intervention [eg, cholecystectomy]).
  11. Has a history of cancer, except basal cell carcinoma that has been in remission for at least 5 years prior to Day 1.
  12. Has a positive test result for hepatitis A, surface antigen, antibody to virus, or at Screening.
  13. Has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 6 weeks prior to Check-in Day -1. Urine test is positive at Screening or Check-in (Day -1).
  14. Has a positive alcohol breath test at the Screening or Check-in (Day -1).
  15. Has confirmed positive result for drugs of abuse at the Screening Visit or Check-in (Day -1).
  16. Has abnormal Screening or Day -1 laboratory values that suggest a underlying disease or participant with the following laboratory abnormalities: has an (ALT) or aspartate aminotransferase (AST) level which exceeds 3* (ULN) set by the testing laboratory at the Screening Visit or Check-in (Day -1).
  17. Has poor peripheral venous access.
  18. Has donated or lost 450 mL or more of his or her blood volume (including plasmapheresis), or had a transfusion of any blood product within 90 days prior to Day 1.
  19. Is unable to understand verbal or written English or any other language for which a certified translation of the and other material supplied for completion by participant is available.
  20. Has a Screening or Check-in (Day -1) abnormal (clinically significant) (ECG). Entry of any participant with an abnormal (not clinically significant) ECG must be approved, and documented by signature by the principal investigator.
  21. Has a marked baseline prolongation of /QTc interval (eg, repeated demonstration of a QTc interval >450 ms) on ECG at the Screening Visit.
  22. Has a history of clinically significant inflammatory disease or allergy (eg, hay fever [hay fever sufferers who do not require medication may be permitted], asthma, eczema), disease (eg, psoriasis, lupus), or history of chronic respiratory disease (eg, emphysema or ).
  23. Has a history of additional risk factors for torsades de pointes (eg, heart failure, hypokalemia, family history of Long QT Syndrome).
  24. Is considered by the investigator, for any reason, to be an unsuitable candidate for participating in this study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    TAK-438 40 mg + Clarithromycin 500 mg

    TAK-438 40 mg, tablets, orally once on Days 1 and 8 along with clarithromycin 500 mg, tablets, orally twice daily from Days 3 to 9.

    Drug: TAK-438 · Drug: Clarithromycin

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for TAK-438 and TAK-438 Metabolites (M-I, M-II, M-III, M-IV-Sul)

    Time frame: Days 1 and 8 pre-dose and at multiple timepoints (up to 48 hours) post-dose

  2. AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-438 and TAK-438 Metabolites (M-I, M-II, M-III, M-IV-Sul)

    Time frame: Days 1 and 8 pre-dose and at multiple timepoints (up to 48 hours) post-dose

  3. AUC∞: Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for TAK-438 and TAK-438 Metabolites (M-I, M-II, M-III, M-IV-Sul)

    Time frame: Days 1 and 8 pre-dose and at multiple timepoints (up to 48 hours) post-dose

  4. AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-438 and TAK-438 Metabolites (M-I, M-II, M-III, M-IV-Sul)

    Time frame: Days 1 and 8 pre-dose and at multiple timepoints (up to 48 hours) post-dose

Secondary outcomes

  1. Ratio of TAK-438 Metabolites Cmax to TAK-438 Cmax

    Time frame: Days 1 and 8 pre-dose and at multiple timepoints (up to 48 hours) post-dose

  2. Ratio of TAK-438 Metabolites AUClast to TAK-438 AUClast

    Time frame: Days 1 and 8 pre-dose and at multiple timepoints (up to 48 hours) post-dose

  3. Ratio of TAK-438 Metabolites AUC∞ to TAK-438 AUC∞

    Time frame: Days 1 and 8 pre-dose and at multiple timepoints (up to 48 hours) post-dose

  4. Ratio of TAK-438 Metabolites AUC(0-24) to TAK-438 AUC(0-24)

    Time frame: Days 1 and 8 pre-dose and at multiple timepoints (up to 48 hours) post-dose

  5. Predose Observed Plasma Concentration of Clarithromycin

    Time frame: Days 3 to 9 pre-dose (-1 hours [1 hour before TAK-438 dosing]) and (11 hours [11 hours after TAK 438 dosing])

  6. Percentage of Participants who Experience at Least One Treatment Emergent Adverse Event (TEAE)

    Time frame: Day 1 until Day 14 or early termination

  7. Percentage of Participants With Markedly Abnormal Laboratory Values

    Time frame: Screening (Days -28 to -2) up to Day 10

  8. Percentage of Participants With Markedly Abnormal Vital Sign Measurements at Least Once Post-dose

    Time frame: Screening (Days -28 to -2) up to Day 10

  9. Percentage of Participants With Markedly Abnormal Safety Electrocardiogram (ECG) Parameters at Least Once Post-dose

    Time frame: Screening (Days -28 to -2) up to Day 10

  10. Percentage of Participants With Clinical Significant Change in Physical Examination

    Time frame: Screening (Days -28 to -2) up to Day 10

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Jenkins H, Jenkins R, Patat A. Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. Clin Drug Investig. 2017 Mar;37(3):311-316. doi: 10.1007/s40261-016-0488-6. PubMed 27928738 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2016
First posted
May 17, 2016
Start
Aug 2010
Primary completionActual
Sep 2010
CompletionActual
Sep 2010
Last update
May 17, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02774902
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
May 17, 2016
Start date
Aug 2010
Primary completion
Sep 2010
Completion
Sep 2010
Last update
May 17, 2016

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion